Current treatment options for patients diagnosed with bone metastatic castrate resistant prostate cancer include second generation androgen deprivation therapies, radiation treatment, bisphosphonates/anti-RANKL therapies, alpharadin and/or chemotherapy1. This evidence concerns the gene TNFSF11 and Familial prostate cancer.